ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 445

FLARE-RA Instrument Detects RA Flares Independent of Disease Activity

Taysir G. Mahmoud1, Michelle Frits2, Christine Iannaccone3, Gabriela Maica4, Vivian P. Bykerk5, Michael Weinblatt6 and Nancy A. Shadick7, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 2Brigham and Women's Hospital, Boston, MA, 3Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 4Department of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital, Boston, MA, 52-005, Mt Sinai Hospital, Toronto, ON, Canada, 6Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 7Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Disease Activity and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Session Title: Rheumatoid Arthritis – Clinical Aspects Poster I: Treatment Patterns and Response

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Clinicians often associate the occurrence of a recent rheumatoid arthritis (RA) flare with an increase in overall disease activity. However, previous studies have shown that patients with RA in low disease states still report flares. The goal of this study is to examine if having a recent flare is independent from disease activity overall, using the FLARE-RA instrument.

Methods: Data were collected from a prospective RA registry including patient reported and clinical outcomes, such as flare frequency and the FLARE-RA instrument. FLARE-RA asks patients to rate 11 statements about their disease on a 0-10 scale (not true to absolutely true). The statements are about patient and physician identified flare features covering the following: morning stiffness, joint pain, joint swelling, sleep disturbance, pain killer or NSAID use, fatigue, decrease in physical activity, irritability, depression, withdrawal, and increased need for help. The score is the mean of all 11 items, where a higher score suggests a recent flare. Disease Activity Score 28 joint with CRP (DAS) was dichotomized into low/remission and moderate/high disease. Flare recency (presence of a flare in the past 6 months) was coded into 3 categories; no flare, at least 1 flare, and currently flaring. Nonparametric tests were performed to examine possible covariates in relation to the FLARE-RA score. A multiple regression model with FLARE-RA score as the outcome included covariates that had a p<0.15 in the univariate analyses.

Results: 503 participants were surveyed; 85% were female with a mean (SD) age of 61 (13), 75% had a college degree or higher, and the median disease duration was 16 (IQR 9, 26) years. The median DAS28-CRP3 was 2.1 (1.6, 2.8) and the median FLARE-RA score was 2 (0.5, 4.4). In univariate analyses, a linear trend between DAS category, flare recency, and FLARE-RA was seen (Figure). The regression model found that having a recent flare is associated with a higher FLARE-RA score independent of DAS category, while adjusting for gender, education, and disease duration. Additionally, flare recency had a higher effect size than DAS on total FLARE-RA score.

Conclusion: Having a current or recent flare drives the FLARE-RA score more than a patient’s current disease activity suggesting that this instrument is able to detect patients’ self report of flare. This instrument may be useful in detecting flares even in patients with low disease activity which could provide an additional rationale for treatment change.

 

 

 

 

 


Disclosure: T. G. Mahmoud, None; M. Frits, None; C. Iannaccone, None; G. Maica, None; V. P. Bykerk, None; M. Weinblatt, Amgen, BMS, Crescendo Bioscience, UCB, Genzyme, 2,Amgen, Abbvie, BMS, Eli Lilly and Company, Gilead, Merck, Pfizer, Novartis, Roche, UCB, Crescendo Bioscience, Genzyme, Samsung, 5; N. A. Shadick, Mallinckrodt, 2,Amgen, 2,Bristol-Myers Squibb, 2,UCB, 2,DxTerity, 2,Sanofi, 2,Crescendo Biosciences, 2,Bristol-Myers Squibb, 5.

To cite this abstract in AMA style:

Mahmoud TG, Frits M, Iannaccone C, Maica G, Bykerk VP, Weinblatt M, Shadick NA. FLARE-RA Instrument Detects RA Flares Independent of Disease Activity [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/flare-ra-instrument-detects-ra-flares-independent-of-disease-activity/. Accessed January 27, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/flare-ra-instrument-detects-ra-flares-independent-of-disease-activity/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences